

NextGen Healthcare (NXGN)

\$15.81 (As of 01/02/20)

Price Target (6-12 Months): **\$17.00**

Long Term: 6-12 Months

Zacks Recommendation:

Neutral

(Since: 01/04/19)

Prior Recommendation: Underperform

Short Term: 1-3 Months

Zacks Rank: (1-5)

4-Sell

Zacks Style Scores:

VGM:B

Value: B

Growth: B

Momentum: C

Summary

NextGen gained from Recurring segment in the last reported quarter. Impressive rates of client addition have been benefiting the company. NextGen witnessed significant deal-size growth in the quarter under review. Solid bookings growth in the quarter deserves a mention as well. Management has retained fiscal 2020 outlook. NextGen exited the fiscal second quarter on a mixed note. Meanwhile, the company's Software, Hardware and Other non-recurring revenues were soft in the quarter under review. Significant contraction in both gross and operating margins raise concern. Additionally, NextGen faces stiff rivalry in the MedTech space. The stock has underperformed the industry over the past year.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$21.12 - \$13.60
20 Day Average Volume (sh)	410,186
Market Cap	\$1.0 B
YTD Price Change	-1.6%
Beta	1.04
Dividend / Div Yld	\$0.00 / 0.0%
Industry	Medical Info Systems
Zacks Industry Rank	Top 36% (92 out of 253)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	4.4%
Last Sales Surprise	-0.1%
EPS F1 Est- 4 week change	-6.2%
Expected Report Date	01/22/2020
Earnings ESP	-1.5%
P/E TTM	19.5
P/E F1	19.1
PEG F1	2.2
P/S TTM	2.0

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2021	138 E	140 E	142 E	145 E	568 E
2020	132 A	134 A	135 E	140 E	542 E
2019	133 A	130 A	131 A	135 A	529 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021	\$0.18 E	\$0.21 E	\$0.20 E	\$0.22 E	\$0.83 E
2020	\$0.16 A	\$0.24 A	\$0.20 E	\$0.22 E	\$0.83 E
2019	\$0.19 A	\$0.24 A	\$0.18 A	\$0.23 A	\$0.86 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 01/02/2020. The reports text is as of 01/03/2020.

Overview

Headquartered in Irvine, CA, NextGen Healthcare, Inc. (NXGN) is a developer and marketer of healthcare information systems.

On Sep 7, 2018, Quality Systems, Inc. (QSII) announced that the company has changed its corporate name to NextGen Healthcare, Inc. On Sep 10, 2018, the company's securities started trading under the new symbol "NXGN."

NextGen recently announced that its cloud-based electronic health record (EHR) ambulatory product, NextGen Office, has completed its integration with CoverMyMeds, the nation's largest electronic prior authorization (ePA) solution.


NextGen offers software that help in automating and streamlining administrative functions required for operating a medical, dental or hospital practice. Its segments also provide software products that automate patient records (replaces paper format) in physician practices, community health centers and hospital settings.

The company reports in four segments:

- Software and Hardware
- Support and Maintenance
- RCM
- EDI
- Professional Services

FY19 at a Glance

Fiscal 2019 revenues totaled \$529.2 million, down 0.8% year over year. Under ASC 605, revenues for the fiscal 2019 amounted to \$134.3 million on a pro forma basis.



Reasons To Buy:

- ▲ **Bookings Surge:** The company witnessed consistent momentum in bookings, which came in at \$133.5 million for the fiscal 2019, up 14.2% from fiscal 2018. At the beginning of fiscal 2019, the company made a commitment to drive substantial bookings growth throughout the year, which is likely to result in revenue growth in fiscal 2020.

In second-quarter fiscal 2020, bookings totaled \$36.6 million, up 1.4% from the year-ago quarter's figure.

- ▲ **Lucrative Prospects in the RCM Space:** NextGen is a major player in the U.S. RCM market. RCM is the financial process (utilizing medical billing software), which healthcare facilities use to keep track on patientcare episodes from registration, appointment scheduling and the final payment of a balance. The global RCM market is anticipated to reach \$73.2 billion by 2026. It is expected to witness a CAGR of 12.0% during the forecast period. Per Frost & Sullivan, RCM is 7.5 times larger than the EHR market.

NextGen Healthcare scored the highest among all ambulatory vendors for its performance in the following key RCM areas – effectiveness of claims processing, patient-facing support performance, efficiency gained by customers, sustainability of pricing and, trust as a business partner. Based on the popularity of the RCM solution, the company plans to expand into dental and hospital markets, which will further drive top-line growth in our view.

NextGen witnessed consistent success in signing all-in deals in its RCM business in the quarter under review.

- ▲ **Big-Data Based Electronic Health Records System:** The latest trend of electronic health record (EHR) services in the U.S. MedTech space has been gaining prominence.

NextGen's NextGen Enterprise and NextGen Office (formerly, MediTouch) software technology and solutions accommodate the unique needs of ambulatory practices of all sizes. These EHR solutions cater to demands like Merit-Based Incentive Payment System (MIPS) requirements, population health needs, and other value-based care initiatives.

According to Transparency Market Research, the global EHR market is estimated to reach \$38.29 billion by 2025, with a CAGR of 5.7%. Reports suggest that MedTech companies with strong exposure to big data automated EHRs will excel in terms of operations and margins.

- ▲ **Recurring Revenue Base:** Strong recurring-revenue base has been a key catalyst. In second-quarter fiscal 2020, total recurring revenues amounted to \$120.6 million, up 3.7% from the year-ago quarter. Recurring revenue growth offsets the decline in perpetual licenses and related services. Per management at NextGen, the growth has been trending in the right direction and enhances the company's future growth curve.

- ▲ **Solid Demand for NextGen Solutions:** Apart from RCM, NextGen will continue to benefit from strong demand for its other NextGen solutions that include Hospitals, EHR and practice management. NextGen's Inpatient Clinicals, Lab and Patient Portal EHR solutions have also been gaining considerable traction. The latest deals in the platforms with EagleDream and Entrada hold promise.

The company's revenue growth continues to be largely boosted by the strength of its NextGen division. We believe that NextGen has strong growth prospects in the ambulatory and hospital software market owing to its product portfolio, which is compliant with the U.S. government's regulatory reforms. New solutions like NextGen Care and NextGen Now are expected to boost the company's presence in health management, ambulatory EHR and practice management segments. The NextGen EHR app for iOS expands the company's mobile efforts to support physicians in high-volume settings.

In May, the company launched its Behavioral Health Suite 3.0, which is a major step in improvement of mental and full-body health.

- ▲ **Acquisition Spree:** In recent times, NextGen signed a significant seven figure all-in deal. Additionally, the company signed six deals over a half a million dollars. Per management, these encouraging signs confirm that the company's complete solution is very competitive in the market and represents continuing opportunity. In recent times, the company closed multiple deals across a broad product spectrum of accounts, both by specialty and geography. In recent past, NextGen announced acquired cloud-based analytics company EagleDream Health. We note that EagleDream Health marks the second major asset acquisition by NextGen Healthcare, following its earlier purchase of Entrada.

During the third quarter, the company acquired TOPAZ information solutions (completed in the last month of the quarter under review). TOPAZ has been a strong reseller partner into the behavioral health space and is likely to bring strong, commercial end solution capabilities to NextGen.

Big-Data based Electronic Health Records, recurring revenue base and solid demand for NextGen solutions are likely to provide NextGen with a competitive edge in the MedTech space.

Reasons To Sell:

▼ **Shares Down:** Shares of NextGen have gained 1.9%, compared with the industry's rally of 28.6%. The current level is below the S&P 500 Index's improvement of 26.3%. Integration risks and intense competition continue to weigh on the stock.

▼ **Q2 Debacle:** In the fiscal second quarter, NextGen's total Software, hardware and other non-recurring revenues totaled \$13.7 million, down 2.4% year over year.

The gross margin in the quarter was 51%, down 210 basis points. Moreover, adjusted operating margin, as a percentage of revenues, was 56.2%, down 340 bps.

▼ **Macroeconomic Sluggishness:** Although government initiatives to digitize healthcare systems has lent strength to such companies, high cost of investments and maintenance cost is likely to impede market growth. Precisely, NextGen has high cost of investments in EHR maintenance, software upgrades and hardware replacement. All of these factors are acting as major deterrents for the global market.

Furthermore, unlike the manufacturers of life-saving devices, the demand for the software company's products is closely tied to budgetary processes of clients, which negatively impacts system sales. Moreover, shrinking opportunities for product sales to physician groups as such groups are increasingly absorbed by hospitals also hurts revenue growth. Strict regulatory environment is another major headwind in this regard.

▼ **Cutthroat Competition in the HCIT Space:** The healthcare information technology (HCIT) market is highly competitive. Also, the industry is exceedingly fragmented and includes numerous players.

Per a research report by Transparency Market Research, leading players in the Global Healthcare Information Systems Market are Cerner Corporation, McKesson and All Scripts. Collectively, these players hold a 26% share of the global market. Thus, competitors seek to gain market traction through lowering prices or offering services that are differentiated from NextGen.

We harbor doubts regarding the company's ability to penetrate the Electronic Health Record (EHR) market where it faces competition from low-priced cloud-based EHR models.

▼ **Unfavorable Product Mix:** Although recurring revenue stream is a positive for NextGen, it mostly comes from the lower margin EDI and RCM services. We believe that the shift in product mix is negatively impacting gross margin. The company expects contributions from services to increase total revenue, which will however be a drag on gross margin expansion in the long run. Moreover, higher research & development as well as selling, general & administrative expenses (increasing headcount, higher marketing expenses) will hurt profitability over the long term.

▼ **Integration Risks:** NextGen continues to acquire businesses that improve its revenue opportunities on one hand and aggravate integration risks on the other. The company's frequent acquisitions can impact its balance sheet in the form of a high level of goodwill and intangible assets. Meanwhile, regular acquisitions are proving to be a distraction for management which can impact the company's overall organic growth. This may limit NextGen's future expansion and worsen the company's risk profile, going forward.

Unfavorable product mix, global economic weakness, intensifying competition and growing integration risk due to frequent acquisitions are major concerns

Last Earnings Report

NextGen Q2 Earnings Beat, Revenues Miss Estimates

NextGen Healthcare reported second-quarter fiscal 2020 adjusted earnings per share of 24 cents, flat with the year-ago quarter's figure. The metric edged past the Zacks Consensus Estimate by a penny.

Revenues totaled \$134.3 million, up 3% year over year. However, the figure missed the Zacks Consensus Estimate by a nominal 0.1%.

Quarter Ending **09/2019**

Report Date	Oct 23, 2019
Sales Surprise	-0.09%
EPS Surprise	4.35%
Quarterly EPS	0.24
Annual EPS (TTM)	0.81

Bookings Update

Bookings for the quarter came in at \$36.6 million, up 1.4% from the year-ago quarter's figure.

Segment Details

The company reported second-quarter fiscal 2020 revenues under the following segments:

Total Recurring revenues grossed \$120.6 million, up 3.7% from the year-ago quarter's figure.

Meanwhile, total Software, hardware and other non-recurring revenues came in at \$13.7 million, down 2.4% on a year-over-year basis. Per management, this reflects headwinds in the managed services and software areas.

Margin

In the quarter under review, gross profit totaled \$68.5 million, down 1%% from the prior-year quarter's tally. Gross margin was 51%, down 210 basis points (bps).

Adjusted operating income in the fiscal second quarter was \$75.4 million, down 3% from the year-ago quarter's figure. Adjusted operating margin, as a percentage of revenues, was 56.2%, down 340 bps.

Fiscal 2020 View Retained

For fiscal 2020, NextGen continues to expect revenues between \$536 million and \$550 million. The Zacks Consensus Estimate for revenues is pegged at \$541.8 million, which is within the guided range.

Full-year EPS are expected between 82 cents and 90 cents. The Zacks Consensus Estimate for EPS is pegged at 85 cents, which is within the projected range.

Recent News

On **Dec 12**, NextGen Healthcare – a leading provider of ambulatory-focused technology solutions – inked a deal to acquire OTTO Health that will allow the acquirer to expand patient capabilities with integrated visits.

Valuation

NextGen's shares are down 20.7% in the past six months while up 1.9% in trailing 12-month periods. Stocks in the Zacks sub-industry are up 0.7% while the Zacks Medical Market is up 4.5% in the past six months. Over the past year, the Zacks sub-industry is up 5.5% and sector is down 8.7%.

The S&P 500 index is up 8.3% in the past six months period and 26.3% in the past year.

The stock is currently trading at 19X Forward 12-months earnings, which compares to 51.04X for the Zacks sub-industry, 21.74X for the Zacks sector and 19.07X for the S&P 500 index.

Over the past five years, the stock has traded as high as 35.31X and as low as 14.22X, with a 5-year median of 23.67X.

Our Neutral recommendation indicates that the stock will perform in line with the market. Our \$17 price target reflects 20.48X forward 12-months earnings.

The table below shows summary valuation data for NXGN.

Valuation Multiples - NXGN					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	19	51.04	21.74	19.07
	5-Year High	35.31	51.04	21.74	19.34
	5-Year Low	14.22	24.52	15.91	15.17
	5-Year Median	23.67	31.96	18.97	17.44
P/S F12M	Current	1.84	2.21	2.88	3.46
	5-Year High	2.66	3.15	3.8	3.46
	5-Year Low	1.29	1.61	2.42	2.54
	5-Year Median	1.81	2.33	2.94	3
P/B TTM	Current	2.65	3.03	4.59	4.41
	5-Year High	4.38	4.47	5.01	4.41
	5-Year Low	2.34	2.13	3.42	2.85
	5-Year Median	3.04	3.08	4.27	3.6

As of 01/02/2020

Industry Analysis Zacks Industry Rank: Top 36% (92 out of 253)



Top Peers

Inovalon Holdings, Inc. (INOV)	Outperform
Cerner Corporation (CERN)	Neutral
Computer Programs and Systems, Inc. (CPSI)	Neutral
Cognizant Technology Solutions Corporation (CTSH)	Neutral
Evolent Health, Inc (EVH)	Neutral
IQVIA Holdings Inc. (IQV)	Neutral
Allscripts Healthcare Solutions, Inc. (MDRX)	Neutral
Premier, Inc. (PINC)	Neutral

Industry Comparison Industry: Medical Info Systems				Industry Peers		
	NXGN Neutral	X Industry	S&P 500	CERN Neutral	EVH Neutral	MDRX Neutral
VGM Score	B	-	-	B	F	B
Market Cap	1.03 B	214.77 M	23.76 B	23.12 B	797.86 M	1.57 B
# of Analysts	12	4	13	15	8	14
Dividend Yield	0.00%	0.00%	1.78%	0.98%	0.00%	0.00%
Value Score	B	-	-	B	D	A
Cash/Price	0.05	0.09	0.04	0.03	0.27	0.09
EV/EBITDA	13.51	-1.30	13.97	16.30	889.06	7.74
PEG Ratio	2.12	1.85	2.02	1.73	NA	1.20
Price/Book (P/B)	2.64	3.47	3.38	5.24	0.71	1.26
Price/Cash Flow (P/CF)	12.24	15.39	13.70	17.30	34.23	5.58
P/E (F1)	18.80	22.58	18.83	23.44	NA	12.58
Price/Sales (P/S)	1.95	3.99	2.68	4.12	0.99	0.89
Earnings Yield	5.25%	-1.37%	5.30%	4.27%	-1.59%	7.95%
Debt/Equity	0.11	0.14	0.72	0.24	0.27	0.51
Cash Flow (\$/share)	1.29	-0.04	6.94	4.26	0.28	1.74
Growth Score	B	-	-	B	F	D
Hist. EPS Growth (3-5 yrs)	-2.76%	13.24%	10.56%	6.89%	NA	21.95%
Proj. EPS Growth (F1/F0)	-3.78%	17.60%	7.41%	17.74%	78.79%	12.29%
Curr. Cash Flow Growth	2.19%	33.26%	14.83%	4.25%	-289.80%	24.91%
Hist. Cash Flow Growth (3-5 yrs)	-2.55%	13.08%	9.00%	13.59%	1.35%	8.69%
Current Ratio	1.29	2.03	1.23	2.21	1.19	0.66
Debt/Capital	9.62%	17.22%	42.92%	19.06%	20.98%	33.83%
Net Margin	3.02%	-17.14%	11.08%	9.02%	-15.02%	12.00%
Return on Equity	10.05%	-19.61%	17.10%	15.61%	-6.93%	5.98%
Sales/Assets	0.97	0.61	0.55	0.80	0.48	0.55
Proj. Sales Growth (F1/F0)	2.45%	21.35%	4.20%	4.10%	8.75%	4.13%
Momentum Score	C	-	-	C	F	C
Daily Price Chg	-1.62%	0.00%	0.33%	0.31%	4.20%	-1.27%
1 Week Price Chg	4.42%	0.00%	0.13%	0.03%	17.06%	1.12%
4 Week Price Chg	-10.63%	0.00%	3.31%	4.03%	41.17%	-3.29%
12 Week Price Chg	2.36%	7.50%	9.70%	10.14%	28.65%	-8.71%
52 Week Price Chg	4.36%	-13.39%	30.28%	45.21%	-51.14%	1.15%
20 Day Average Volume	410,186	230,361	1,603,615	1,477,624	2,075,669	1,708,688
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
(F1) EPS Est 4 week change	-6.17%	0.00%	0.00%	0.20%	0.00%	0.00%
(F1) EPS Est 12 week change	-4.49%	-1.00%	-0.57%	-2.33%	-6.20%	2.38%
(Q1) EPS Est Mthly Chg	-14.67%	0.00%	0.00%	0.00%	0.00%	0.00%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	B
Growth Score	B
Momentum Score	C
VGM Score	B

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.